<DOC>
	<DOC>NCT00144664</DOC>
	<brief_summary>This is an open-label, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with pJIA.</brief_summary>
	<brief_title>Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Inclusion criteria Patients who are diagnosed with rheumatoid factor (RF) positive or negative polyarthritic or oligoarthritic JIA according to the ILAR standards (1997) Patients aged at least 2 years old and less than 20. Patients aged less than 16 years old at time of onset Exclusion criteria Patients with Class IV Steinbrocker functional disorder at evaluation within 2 weeks before initiation of treatment with the investigational product Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept, within 12 weeks before initiation of treatment with the investigational product</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>